Seed funding
Copenhagen University spin-out EpiTherapeutics has won seed funding from Novo A/S and SEED Capital Denmark to advance the discovery and development of cancer treatments based on research epigenetics, the study of the mechanisms that are involved in the regulation of gene expression.
Epigenetics processes are master regulators that enable gene expression to be turned on and off to maintain normal cellular function. In recent years it has become clear that epigenetic control mechanisms do not function properly in cancer and some metabolic diseases, including diabetes. EpiTherapeutics will focus on the discovery of drugs that target these mechanisms to selectively regulate their activity.
EpiTherapeutics’ lead development programme is focused on an enzyme involved in the regulation of androgen-responsive genes for the treatment of prostate cancer.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
